CHAI and global partners in the Diagnostics Access Initiative have joined with Roche Diagnostics to announce a 35 percent reduction in the price for HIV early infant diagnostic technologies. The new access price is US$9.40 per test, including proprietary reagents and...
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV London, May 26, 2015 - ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative,...
An agreement announced today will reduce the achievable cost per use of the non-pneumatic anti-shock garment (NASG) by over 75 percent and expand access to this innovative new product, which has been shown to safely and effectively reduce mortality due to post-partum hemorrhage, a leading cause of the nearly 290,000 maternal deaths reported annually around the world.
The U.S. Centers for Disease Control and Prevention (CDC) is leading a consortium of malaria partners aiming to eliminate indigenous cases of malaria on the island of Hispaniola by 2020.
The 2013 Annual Report highlights CHAI's programmatic work around the world, thanks to our many dedicated partners and supporters.
Roche today announced a major Global Access Program to sharply lower the price of HIV viral load tests in low- and middle-income countries. This new initiative creates a ceiling price of US$9.40 per test, and will reduce Roche’s average price by more than 40 percent in low- and middle-income countries.
